Financial Performance - Revenues for the three months ended March 31, 2024, were $640,000, a decrease from $2.679 million in the same period of 2023[7] - Total operating expenses increased to $74.169 million in Q1 2024 from $50.657 million in Q1 2023, representing a 46.5% increase[7] - Net loss for the three months ended March 31, 2024, was $66.930 million, compared to a net loss of $45.995 million in the same period of 2023, reflecting a 45.4% increase in losses[7] - The company reported an accumulated deficit of $720.6 million as of March 31, 2024[12] - The company anticipates continued net losses and plans to raise additional capital through equity offerings, debt financings, or collaborations[12] - The company reported a net loss of $66,930 for the three months ended March 31, 2024, compared to a net loss of $45,995 for the same period in 2023[30] - The company incurred cumulative net losses of $720.6 million as of March 31, 2024, with expectations of increased expenses and operating losses due to ongoing clinical trials and research activities[62] - The company anticipates continued net losses for the foreseeable future, with no products approved for sale yet[76] Cash and Liquidity - As of March 31, 2024, the company had $901.0 million in unrestricted cash, cash equivalents, and investment securities, sufficient to meet funding requirements for at least the next 12 months[12] - The company had cash, cash equivalents, and restricted cash of $397,224 at the end of the period, compared to $42,494 at the end of the same period in 2023[30] - Net cash used in operating activities was $52,856 for the three months ended March 31, 2024, compared to $40,718 in the same period of 2023[30] - The company provided $393,574 in net cash from financing activities during the three months ended March 31, 2024, significantly higher than $484 in the prior year[30] - The company reported unrestricted cash, cash equivalents, and investment securities of $901.0 million as of March 31, 2024, with an accumulated deficit of $720.6 million[76] - Net cash provided by financing activities was $393.6 million in Q1 2024, significantly up from $0.5 million in Q1 2023, due to proceeds from the sale of common stock[99] - Cash and cash equivalents rose significantly to $395,924 thousand from $54,897 thousand, indicating a substantial liquidity improvement[168] Research and Development - The company plans to submit a New Drug Application for paltusotine for the treatment of acromegaly to the FDA in the second half of 2024, with potential approval in 2025[17] - Positive topline results from a Phase 2 study of paltusotine showed rapid and sustained reductions in bowel movement frequency and flushing episodes in patients with carcinoid syndrome[18] - The company is conducting a Phase 2 study of CRN04894 in CAH patients, with initial data expected in the second quarter of 2024[23] - The company has initiated a clinical trial of CRN04894 in patients with Cushing's disease, with initial data expected in the second quarter of 2024[24] - Research and development expenses increased to $53,341,000 for the quarter ended March 31, 2024, up from $38,468,000 in the same quarter of 2023, representing a rise of $14,873,000[73] - Research and development expenses rose to $53.3 million in Q1 2024 from $38.5 million in Q1 2023, driven by a $9.4 million increase in personnel costs and higher outside services[95] - The company expects to select a development candidate for its SST3 agonist program in the first half of 2024, targeting Autosomal Dominant Polycystic Kidney Disease (ADPKD) which affects 1 in 1,000 individuals[57] - Research and development expenses for the paltusotine program were $13.0 million for the quarter ended March 31, 2024, compared to $12.4 million in the same quarter of 2023, primarily due to increased manufacturing activities[74] Collaborations and Investments - The company entered into a collaboration and license agreement with Radionetics for the development of radiotherapeutics in October 2021[40] - The Company acquired a 64% majority stake in Radionetics through the exchange of 50,500,000 shares of common stock and a warrant to purchase additional shares[42] - In August 2023, the Company invested $5.0 million to purchase 14,404,656 shares of preferred stock in Radionetics, alongside other investors[42] - The Company's ownership stake in Radionetics decreased from 55% to 31% following the August 2023 transaction, resulting in net dilution[42] - As of March 31, 2024, the Company's investment in Radionetics was written down to zero, with equity method losses recorded at $0.5 million for the quarter[43] - The Company recognized $0.6 million in revenue from the estimated transaction price of $14.0 million during the three months ended March 31, 2024[49] - The Company completed a private placement offering of 8,333,334 shares of common stock at $42.00 per share, generating net proceeds of approximately $335.5 million[51] - The Company issued 1,223,775 shares of common stock in an ATM Offering for net proceeds of approximately $43.4 million during the three months ended March 31, 2024[52] Stock and Equity - The total stock options outstanding increased to 14,456,739 as of March 31, 2024, with an average exercise price of $23.17[36] - The weighted-average fair value of stock options awarded was $27.38 per share for the three months ended March 31, 2024, compared to $12.29 per share in the prior year[38] - Unrecognized stock-based compensation cost related to option awards was $150.4 million as of March 31, 2024, expected to be recognized over a remaining weighted-average period of 2.2 years[39] - The company granted 873,886 restricted stock units during the three months ended March 31, 2024, with an average grant date fair value of $43.51[37] - The company had 78,859,510 shares of common stock outstanding as of May 6, 2024[165] Market and Economic Conditions - The company has been impacted by changes in U.S. and international trade policies, particularly tariffs and export controls affecting products manufactured in China[121] - Cybersecurity risks are increasing due to reliance on information technology systems, with potential vulnerabilities from various cyber threats[122] - The company is exposed to foreign currency exchange rate risk, with net realized and unrealized losses from foreign currency transactions totaling ($186,000) for the three months ended March 31, 2024[117] Future Plans and Development - The company is focused on developing oral nonpeptide therapeutics targeting peptide GPCRs for endocrine diseases, with a pipeline including paltusotine for acromegaly and carcinoid syndrome[133] - The company is developing TSHR antagonists for Graves' disease and Thyroid Eye Disease, with plans to select a development candidate in 2024[83] - The company expects to select a development candidate for its parathyroid hormone antagonist program in the first half of 2024[45] - The company is advancing additional product candidates through preclinical studies alongside paltusotine[133] - The open label extension phases of the PATHFNDR trials for paltusotine are ongoing[139]

Crinetics Pharmaceuticals’ (CRNX) shares gained 19.1% on Mar 19 after the company reported positive top-line data from the second (PATHFNDR-2) of two late-stage studies evaluating the efficacy and safety of lead candidate, paltusotine, for the treatment of acromegaly.Acromegaly is a rare endocrine disease generally caused by a pituitary adenoma, which is a non-cancerous tumor in the pituitary that secretes growth hormone.The PATHFNDR-2 study is evaluating paltusotine, an oral SST2 agonist, in participants w ...

Crinetics Pharmaceuticals, Inc. (CRNX) shares ended the last trading session 19.1% higher at $45.18. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 0.3% gain over the past four weeks.The sudden surge in the stock price was observed after Crinetics reported achieving primary and all key secondary endpoints, with statistical significance, in the second (PATHFNDR-2) of two late-stage studies evaluating the efficacy a ...

56% of Participants on Paltusotine Achieved IGF-1 ≤1.0 xULN vs. 5% on Placebo (p<0.0001) Paltusotine was Generally Well-tolerated with No Serious Adverse Events Positive Topline Results Support Planned NDA Submission to the FDA in 2H 2024 Management Will Host a Conference Call Today at 8:30 a.m. Eastern Time SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel t ...

Paltusotine Treatment Demonstrated Rapid and Sustained Reductions in Frequency and Severity of Flushing Episodes and Bowel Movements Paltusotine was Generally Well-Tolerated and Showed an Overall PK Profile Consistent with Prior Studies Results Confirm Initial Positive Data Previously Reported Management to Host a Conference Call Today at 4:30 p.m. Eastern Time SAN DIEGO, March 12, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) a clinical stage pharmaceutical company focused on the ...

SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that on March 10, 2024, the Compensation Committee of Crinetics' Board of Directors granted non-qualified stock option awards to purchase an aggregate of 42,450 shares of its common stock to five new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the "2021 Inducement Plan"). The stock options were granted as inducements material to th ...

koya79 Financial and Clinical Progress Positions Crinetics for Market Leadership Much has changed at Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) since my first look nearly a year ago. Back then, I expressed concern over their oral solution for acromegaly and made the argument that paltusotine, by the nature of its oral administration, would likely not be able to replicate the efficacy and safety of existing subcutaneous drugs like octreotide. Nonetheless, I did recognize the potential of Crinetics' dr ...

Financial Data and Key Metrics Changes - The company reported a net loss of $60.1 million for Q4 2023, compared to a net loss of $45 million for the same period in 2022, and a full-year net loss of $214.5 million in 2023 versus $163.9 million in 2022 [68] - Research and development expenses increased to $45.6 million for Q4 2023 and $168.5 million for the full year, up from $37 million and $130.2 million in 2022, primarily due to higher personnel costs and increased outside services [14] - General and administrative expenses rose to $17.1 million for Q4 2023 and $58.1 million for the full year, compared to $11.3 million and $42.4 million in 2022, attributed to higher personnel costs [40] - Revenues were $4 million for the full year 2023, down from $4.7 million in 2022, with no revenues reported for Q4 2023 compared to $0.7 million in Q4 2022 [41] Business Line Data and Key Metrics Changes - The PATHFNDR-1 trial for Paltusotine in acromegaly achieved its primary endpoint with 83% of patients meeting the target, compared to only 4% in the placebo group, demonstrating a highly statistically significant difference [4][3] - In the ongoing PATHFNDR-2 trial, 111 participants were enrolled, and top-line results are expected to be shared soon, with the goal of seeking a broad indication for Paltusotine in treating acromegaly [13][23] - For carcinoid syndrome, initial results from a Phase 2 trial showed a 65% reduction in excess bowel movement frequency and flushing episodes, indicating promising efficacy [64][35] Market Data and Key Metrics Changes - The combined market opportunity for acromegaly and carcinoid syndrome is projected to be multi-billion dollars, prompting the company to build out its commercial organization and identify key prescribers [30] - The company anticipates a potential launch of Paltusotine in 2025, focusing on developing commercial capabilities for these markets [30] Company Strategy and Development Direction - The company aims to complete multiple transformative milestones in 2024 and 2025, including the completion of PATHFNDR-2 and the initiation of Phase 3 studies in carcinoid syndrome and congenital adrenal hyperplasia (CAH) [2] - The strategy includes expanding the pipeline with multiple preclinical programs targeting various endocrine-related diseases, including a parathyroid hormone receptor antagonist and a TSH antagonist [24] - The company is focused on building a strong commercial organization to support the launch of Paltusotine and enhance market access [30] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming year, highlighting the transformative potential of 2024 for the company as it progresses with regulatory submissions and commercialization efforts [70] - The management team emphasized the importance of patient-centric data and symptom control in their discussions with payors and physicians, which will be crucial for the commercial strategy [83][104] Other Important Information - The company announced a private placement equity financing of approximately $350 million, strengthening its financial position with a pro forma cash balance of approximately $900 million [54][67] - The company expects its cash burn to be approximately $50 million to $60 million per quarter in 2024, with sufficient funds to support operations into 2028 [69] Q&A Session Summary Question: What is the status of PATHFNDR-2 and patient eligibility? - Management clarified that patients not currently receiving medical therapy are enrolled, and those previously unresponsive to SRLs are excluded from the trial [43][7] Question: What are the expectations for the carcinoid syndrome data? - Management expressed that a win for the final data set would be confirming the interim results and providing more information on exploratory endpoints [78] Question: How important is the acromegaly symptoms diary for labeling? - Management highlighted that while biochemical control is a regulatory endpoint, symptom control is crucial for patient satisfaction and will be a significant part of the commercial strategy [82][83] Question: What is the commercial strategy for Paltusotine? - The strategy involves discussions with payors regarding pricing and the value proposition of Paltusotine compared to injectable therapies, emphasizing potential cost savings [85][104] Question: What are the baseline characteristics for PATHFNDR-2? - Management indicated that they have not yet completed the analysis of baseline characteristics but expect the patient demographics to be representative of the general population [108]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38583 Crinetics Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpora ...

SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) ("Crinetics" or the "Company"), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today that it has agreed to sell 8,333,334 shares of its common stock at a price of $42.00 per share to a select group of institutional and accredited healthcare specialist investors in an oversubscr ...